JXJianmin Xu

Jianmin Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianmin Xu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Yunshi Zhong

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    7 shared publications
  • Li Ren

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    5 shared publications
  • Ye Wei

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    4 shared publications
  • Dexiang Zhu

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    3 shared publications
  • Jian Zhou

    Zhongshan Hospital, Fudan University

    3 shared publications
  • Xinyu Qin

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    3 shared publications

Latest Publications

  • Serum proteomic profiling for the early diagnosis of colorectal cancer

    by Dexiang Zhu, Jie Wang, Li Ren, Yan Li, Bin Xu, Ye Wei, Yunshi Zhong, Xinzhe Yu, Shenyong Zhai, Jianmin Xu, et al.

    No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Magnetic bead‐based fractionation coupled with MALDI‐TOF MS was used to screen serum samples from CRC patients, healthy controls, and other cancer patients. A diagnostic model with five proteomic features (m/z 1778.97, 1866.16, 1934.65, 2022.46, and 4588.53) was generated using Fisher algorithm with best performance. The Fisher‐based model could discriminate CRC patients from the controls with 100% (46/46) sensitivity and 100% (35/35) specificity in the training set, 95.6% (43/45) sensitivity and 83.3% (35/42) specificity in the test set. We further validated the model with 94.4% (254/269) sensitivity and 75.5% (83/110) specificity in the external independent group. In other cancers group, the Fisher‐based model classified 25 of 46 samples (54.3%) as positive and the other 21 as negative. With FT‐ICR‐MS, the proteomic features of m/z 1778.97, 1866.16, 1934.65, and 2022.46, of which intensities decreased significantly in CRC, were identified as fragments of complement C3f. Therefore, the Fisher‐based model containing five proteomic features was able to effectively differentiate CRC patients from healthy controls and other cancers with a high sensitivity and specificity, and may be CRC‐specific. Serum complement C3f, which was significantly decreased in CRC group, may be relevant to the incidence of CRC. J. Cell. Biochem. 114: 448–455, 2013.


  • Outcome of Patients with Colorectal Liver Metastasis: Analysis of 1,613 Consecutive Cases

    by Zhu Dexiang, Ren Li, Wei Ye, Wu Haifu, Zhong Yunshi, Ye Qinghai, Zhai Shenyong, Xu Bo, Liang Li, Pan Xiangou, et al.

    This study was designed to evaluate the long-time outcome of patients with colorectal liver metastasis (CRLM) undergoing different types of therapy and identify prognosis factors. From 2000 to 2010, 1,613 consecutive patients with CRLM were identified. Clinicopathological and outcome data were collected and analyzed by univariate and multivariate analyses. Synchronous liver metastasis (SLM), female, grade III-IV, T4 and N positive of primary tumor, bilobar disease, number of liver metastases ≥4, size of largest liver metastases ≥5 cm, serum CEA level ≥5 ng/ml, and CA19-9 level ≥37 u/ml were the predictors of adverse outcome using univariate analysis. The median survival and 5-year survival rate for patients after resection of liver metastases was 49.8 months and 47%, better than that for those after other therapy. In addition, patients without treatment had the poorest survival. Sixty-four initially unresectable patients underwent surgery after conversion therapy with a median survival of 36.9 months and a 5-year survival of 30%. By multivariate analysis, SLM, poorly differentiated primary tumor, number of liver metastases ≥4, size of largest liver metastases ≥5 cm, and no surgical treatment of liver metastases were found to be independent predictors of poor survival. Patients with CRLM could get long-term survival benefit from different types of therapy, and resection of liver metastases was the optimal strategy. A predictive model using these above five factors may be of use in stratifying patients who may benefit from intensive surveillance and adjuvant therapy.


  • Top Cited Papers

    Enhanced Recovery After Surgery (ERAS) Program Attenuates Stress and Accelerates Recovery in Patients After Radical Resection for Colorectal Cancer: A Prospective Randomized Controlled Trial

    by Li Ren, Dexiang Zhu, Ye Wei, Xiangou Pan, Li Liang, Jianmin Xu, Yunshi Zhong, Zhanggang Xue, Ling Jin, Shaokang Zhan, et al.

    Background: The aim of this trial was to compare the Enhanced Recovery After Surgery (ERAS) program with conventional perioperative management in patients who underwent radical resection for colorectal cancer.Methods: A combination of evidence‐based and consensus methodology was used to develop the ERAS protocol. Five hundred ninety‐seven consecutive patients who underwent elective colorectal resection were randomized to either the ERAS (n = 299) or the control group (n = 298). Outcomes relating to nutrition and metabolism index, stress index, and recovery index were measured and recorded.Results: Demographic and operative data were similar between the two groups. Patients in the ERAS group showed improved nutritional status when compared with those of the control group. On postoperative day (POD) 1, the HOMA‐IR (insulin resistance index) of the ERAS group was lower than that of the control group (p < 0.001). The cortisol level of the control group was elevated on both POD 1 (p = 0.007) and POD 5 (p = 0.002) compared to the preoperative level. However, the cortisol level of the ERAS group was not increased until POD 5 (p = 0.001). Reduced levels of TNF‐α, IL‐1β, IL‐6, and IFN‐γ in the ERAS group indicated less postoperative stress responses. In addition, ERAS was associated with accelerated recovery of gastrointestinal function. The postoperative length of stay (p < 0.001) and expense (p < 0.001) for the ERAS group were reduced in comparison to the controls. Twenty‐eight cases in the control group and twenty‐nine in the ERAS group suffered complications, which was not significantly different.Conclusion: The ERAS protocol attenuates the surgical stress response and accelerates postoperative recovery without compromising patient safety.


    • 1 March 2010
      • Vol. 48  (5) , 327-9

    [More on new concepts of the surgical management of colorectal liver metastases].

    by Jian-Min Xu, Yun-Shi Zhong, Xin-Zhe Yu

  • Immunonutrition in Surgical Patients

    by J. Xu, Z. Yunshi, R. Li

    Purpose of the review: To outline recent findings concerning the efficacy of immunonutrients in patients undergoing surgery. Recent findings: Surgery induces an inflammatory response that can become excessive and damaging in some patients. The major risk factors are pre-existing nutritional status and increasing levels of surgical stress. A range of nutrients, including several amino acids, antioxidant vitamins and minerals, ω-3 fatty acids, and nucleotides, are able to modulate inflammation and the associated oxidative stress, and maintain or improve immune function. Considering the overall treatment effect of immune-modulating nutrients, parenteral glutamine is recommended in patients receiving parenteral nutrition, while enteral glutamine should be considered for burn and trauma patients. Antioxidants, particularly selenium, should be considered for critically ill patients, and enteral formulas enriched with fish oils are recommended for patients with acute respiratory distress syndrome. Arginine-supplemented diets are not recommended. In summary, malnourished patients should receive preoperative artificial nutrition for at least 10 days prior to major surgery and for 7 days postoperatively. Enteral nutrition is the best support for these patients. The benefit of immuneenhancing diets in severely malnourished patients remains to be proven. Preoperative oral immunonutrition (arginine, omega-3 fatty acids, and nucleotides) is indicated for non-malnourished patients. Although patients with cancer exhibit some special metabolic features, preoperative immunonutrition is also indicated. Summary: Immunonutrition is effective in improving outcome in a wide range of patients, particularly in malnourished individuals. However, further research using larger, better-designed trials is needed to assess whether immune function is benefited, with an improved clinical outcome in vulnerable patients.


  • Hepatectomy for liver metastasis of colorectal cancer

    by Jianmin Xu, Ye Wei, Yunshi Zhong, Jia Fan, Jian Zhou, Lunxiu Qin, Li Ren, Xinyu Qin


  • Effect of Dietary Fiber and Growth Hormone on Colonic Adaptation in Short Bowel Syndrome Treated by Enteral Nutrition

    by Jianmin Xu, Yunshi Zhong, Dayong Jin, Hongwei Zhang, Zhaohan Wu

    Background: Colon adaptation can partially compensate for the reduced capacity of nutrient absorption in patients with short bowel syndrome (SBS).Objective: The aim of this study was to assess the effect of combined treatment with enteral nutrition (EN), dietary fiber, and recombinant human growth hormone (rhGH) on promoting colonic adaptation.Methods: A group of 40 male Sprague‐Dawley rats undergoing up to 80% to 85% small intestine resection were randomly assigned to four groups of 10 rats each: enteral nutrition (EN, the control); enteral nutrition/dietary fiber (EF); enteral nutrition/rhGH (EG); and enteral nutrition/dietary fiber/rhGH (EFG). All groups received isonitrogenous, isocaloric enteral feeding for 21 days. Body weight, daily nitrogen balance, colonic morphology, DNA, insulin‐like growth factor‐1/IGF‐1 receptor (IGF‐1)/IGF‐1R) expression were determined.Conclusion: Morphologic adaptation of the colon (including increased mucosal thickness and plica height, enlarged surface area, increased hyditloid cells) was observed on postoperative day 21. GH is superior to fiber in several aspects: increasing colon diameters (0.46 ± 0.03 vs. 0.38 ± 0.02 cm, P < 0.05), villous height (356 ± 23 vs. 307 ± 21 μm, P < 0.05) and total surface area (15,222 ± 1344 vs. 13,178 ± 1727 μm2, P < 0.05). Increased DNA content—1.66 ± 0.13 (EG) and 1.71 ± 0.13 (EGF) vs. 1.28 ± 0.11(EF), P < 0.05—in the colon was also found in the EG and EGF groups. GH administration led to a significant increase in plasma IGF‐1 (439.6 ± 88.3 ng/ml in the EG group, 455.4 ± 107.4 ng/ml in the EGF group) and growth hormone (9.29 ± 6.49 ng/ml in the EG group, 9.68 ± 3.26 ng/ml in the EGF group) as compared to the EN group (IGF‐1, 328.7 ± 68.1 ng/ml; GH, 5.81 ± 2.41 ng/ml) and the EF group (IGF‐1, 356.4 ± 52.1 ng/ml; GH, 6.51 ± 4.66 ng/ml). Analysis of IGF‐1 and IGF‐1 receptor mRNA also demonstrated a significantly higher IGF‐1 mRNA in the EG and EFG groups than in the EN and EF groups. Colon functional adaptation was also associated with accelerated absorptive function of water in the EF, EG, and EGF groups. Improved nutritional status (body weight, nitrogen retention, plasma protein) were seen in the EG and EGF groups. Dietary fiber, in combination with growth factor, synergistically promoted colon adaptation in the SBS animal model and facilitated maintenance of daily nutritional needs in rodents.


    • 1 April 2007
      • Vol. 45  (7) , 452-4

    [Therapeutic effects of hepatic resection in liver metastasis of colorectal cancer].

    by Jian-Min Xu, Yun-Shi Zhong, Jia Fan, Jian Zhou, Lun-Xiu Qin, Wei-Xin Niu, Ye Wei, Li Ren, Yan-Han Lai, De-Xiang Zhu, et al.

    To evaluate therapeutic effects of hepatic resection in liver metastasis of colorectal cancer (LMCC). The clinical data of 133 cases of LMCC received hepatic resection from January 1, 2000 to December 31, 2005 in Zhongshan Hospital were analyzed retrospectively. The relationship between hepatic resection and survival rate was also concerned. One hundred and thirty-three cases received curative hepatic resection in all 470 LMCC cases, of which 30 cases from synchronous liver metastasis (SLM) group (totaled 196 cases) and 103 cases from metachronous liver metastasis (MLM) group (totaled 274 cases). Mortality rate during operation was 3.3% in SLM and 1.9% in MLM (P < 0.05). All patients were followed-up till June 31, 2006, the 1, 3, 5 year survival rates and median survival time of SLM were similar to those of MLM, but its recurrence rate was higher (36.7% vs 20.4%, P = 0.030). The 1, 3, 5 year survival rate in the 49 patients who were operable but received non-operation treatment were significantly lower than those in operated patients (P = 0.003). In 30 SLM cases, 22 received I stage resection of their primary and liver metastasis tumor and 8 received liver metastasis resection after the primary surgery (II stage operation), 1, 2, 3 year survival and the median survival time were similar in the two groups. With COX multivariate analysis, incision margin > or = 1 cm (P = 0.036) and reoperation after recurrence (P = 0.041) were protective survival factors, and post-operation recurrence (P = 0.023) was survival risk factor. Curative hepatic resection is the first choice of therapy in liver metastasis of colorectal cancer and it can improve survival.


  • Preoperative Hepatic and Regional Arterial Chemotherapy in the Prevention of Liver Metastasis After Colorectal Cancer Surgery

    by Jianmin Xu, Yunshi Zhong, Niu Weixin, Qin Xinyu, Lai Yanhan, Ren Li, Wang Jianhua, Yan Zhiping, Cheng Jiemin

    To investigate whether preoperative hepatic and regional arterial chemotherapy is able to prevent liver metastasis and improve overall survival in patients receiving curative colorectal cancer resection. Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n = 110) or surgery alone (control group, n = 112). The primary endpoint was disease-free survival, whereas the secondary endpoints included liver metastasis-free survival and overall survival. There were no significant differences in overall morbidity between PHRAC and Control groups. During the follow-up period (median, 36 months), the median liver metastasis time for patients with stage III CRC was significantly longer in the PHRAC group (16 +/- 3 months vs. 8 +/- 1 months, P = 0.01). In stage III patients, there was also significant difference between the 2 groups with regard to the incidence of liver metastasis (20.6% vs. 28.3%, P = 0.03), 3-year disease-free survival (74.6% vs. 58.1%, P = 0.0096), 3-year overall survival (87.7% vs. 75.7%, P = 0.020), and the median survival time (40.1 +/- 4.6 months vs. 36.3 +/- 3.2 months, P = 0.03). In the PHRAC arm, the risk ratio of recurrence was 0.61 (95% CI, 0.51-0.79, P = 0.0002), of death was 0.51 (95% CI, 0.32-0.67; P = 0.009), and of liver metastasis was 0.73 (95% CI, 0.52-0.86; P = 0.02). In contrast, PHRAC seemed to be no benefit for stage II patients. Toxicities, such as hepatic toxicity and leukocyte decreasing, were mild and could be cured with medicine. Preoperative hepatic and regional arterial chemotherapy, in combination with surgical resection, could be able to reduce and delay the occurrence of liver metastasis and therefore improve survival rate in patients with stage III colorectal cancer.